All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given.  View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Decitabine therapy in AML patients with monosomal karyotype

By Cynthia Umukoro

Share:

Feb 15, 2018


Decitabine (DEC) therapy improved response rate and led to a longer Progression Free Survival (PFS) in older Acute Myeloid Leukemia (AML) patients with Monosomal Karyotype (MK) according to results of a sub-analysis of the phase III randomized DACO-016 study (NCT00260832), published in American Journal of Hematology by Agnieszka Wierzbowska [member of the AML Global Portal (AGP) European Steering Committee] from the Medical University of Lodz, Lodz, PL, and colleagues.1

The phase III randomized DACO-016 study compared DEC versus Treatment Choice (TC) in older patients with newly diagnosed AML. Findings of this study demonstrated that DEC led to an improved complete response rate and a longer Overall Survival (OS) compared to TC in older newly diagnosed AML.2 Wierzbowska et al., conducted a post-hoc analysis whose main objectives were to determine the effects of DEC versus TC on outcomes of AML patients with MK+ disease, and to compare versus MK− AML with other unfavorable karyotypes.1

In this DACO-016 study, 485 newly diagnosed AML patients were randomly assigned to either receive decitabine (20 mg/m2 /day for 5 consecutive days every 4 weeks) or TC (best supportive care or cytarabine 20 mg/m2/day for 10 days every 4 weeks).  Of these, patients with MK+ (n = 64 [DEC, n = 33, TC, n = 31]) and MK- with poor cytogenetics (n = 99 [DEC, n = 49, TC, n = 50) were identified and included in this post-hoc analysis.

Key findings:

  • MK+ group

    • Overall Response Rate (ORR) in the DEC and TC arm: 36% (12/33) vs 3% (1/31), P = 0.0013
    • Median PFS in the DEC and TC arm: 2.6 vs 1.3 months, HR = 0.53 (95% CI, 0.31 – 0.90), P = 0.0181
    • Median OS in the DEC and TC arm: 6.3 vs 2.6 months, HR = 0.67 (95% CI, 0.39 – 1.15), P = 0.141
  • MK- poor-risk cytogenetics group

    • ORR in the DEC and TC arm: 18% (10/49) vs 12% (6/50), P = 0.287
    • Median PFS in the DEC and TC arm: 2.4 vs 2.2 months, HR = 1.13 (95% CI, 0.74 – 1.72], P = 0.576
    • Median OS in the DEC and TC arm: 5.0 vs 4.7 months, HR = 1.13 (95% CI, 0.72 – 1.70), P = 0.576
  • In the TC arm, there was a trend for poorer OS in MK+ patients compared to patients who were MK-: 2.6 vs 4.7 months respectively, HR = 1.52 (95% CI, 0.91 – 2.54), P = 0.107
  • In the DEC arm, median OS was similar between MK+ and MK- patients: 6.3 vs 5.0 months respectively, HR = 0.98 (95% CI, 0.60 – 1.58), P = 0.924

The authors concluded by highlighting that DEC “improved response rates and PFS compared with other standard therapies for patients who were ineligible for intensive chemotherapy, with a benefit of almost 4 months in median OS”.  Furthermore, "decitabine may overcome the extremely poor prognosis associated with MK, and may be a beneficial initial treatment in these patients".

Key limitations of this post-hoc study include the open-label design of the DACO-016 study, the post-hoc nature of the analysis, and the relatively small number of patients. The authors noted that the findings of this post-hoc analysis should be confirmed in large prospective studies.

References